secwatch.observer — SEC 8-K summary
======================================

Issuer:     CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL)
CIK:        0001100682
Form:       8-K
Filed at:   2026-08-05T11:15:21+00:00
Accession:  0001100682-26-000115
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Charles River Q2: revenue $1.00B, GAAP loss $(0.03), non-GAAP EPS $3.02; guidance raised
--------------------------------------------------------------------------------

- Revenue $1.00B, down 2.7% YoY; organic revenue +0.1%, first positive since Q3 2023.
- GAAP net loss $(1.5)M ($(0.03)/diluted share) vs net income $52.3M ($1.06) in Q2 2025; loss driven by $63.7M divestiture loss.
- Non-GAAP EPS $3.02, down 3.2% from $3.12; non-GAAP operating margin 20.5% vs 22.1% YoY.
- Raises 2026 guidance: organic revenue growth now 0.0%-1.0% (prior -1.5% to -0.5%); non-GAAP EPS $11.15-$11.45 (prior $10.80-$11.30).
- Repurchased $100M of stock in Q2 at avg $174/share; $700M remaining under $1B authorization.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1100682/000110068226000115/0001100682-26-000115-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1100682/000110068226000115/crl-20260805.htm
  HTML page:      https://secwatch.observer/filing/0001100682-26-000115

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer